MedTrace Logo

A Study of Multiple Oral Doses of IX-01 in Healthy Male Subjects

NCT02792647 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2016-11-10

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and tolerability of IX-01 after multiple doses, and to determine the PK of IX-01 and activity of CYP3A4.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Placebo

Administered orally

DRUG

IX-01

Administered orally

Sponsors & Collaborators

  • Ixchelsis Limited

    lead INDUSTRY

Principal Investigators

  • Franz van den Berg, MBChB · Hammersmith Medicines Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2016-07-31
Completion
2016-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02792647 on ClinicalTrials.gov